Research Library — FDA — Page 2 | Reta Compare
50 research articles in FDA. Page 2 of 2.
Articles
- FDA and State Board Coordination on Compounding
- FDA Warning Letter Language: Reading Between the Lines
- FDA's Stance on Compounded Retatrutide
- The FDA Untitled Letter Explained
- FDA Injunctions Against Compounded Peptide Pharmacies
- FDA Consent Decrees in Compounded GLP-1 Enforcement
- FDA Criminal Referrals for Compounded Drug Violations
- FDA Enforcement Reports: Quarterly Trends in 2026
- FDA's New Office of Compounding Quality
- How FDA Coordinates With DEA on Peptide Matters
- FDA Oversight of Digital Pharmacies and Telehealth
- FDA Rulemaking on Compounded Peptides: What's in Process
- FDA Foreign Inspections of GLP-1 API Manufacturers
- FDA Warning Letters: Compounded Semaglutide Versions
- FDA Actions Against 'Research Peptide' Retailers
- FDA and the 2026 Shortage Resolution Reviews
- How FDA Processes Citizen Petitions on Compounded Drugs
- FDA User Fees and Their Role in Compounded Drug Oversight
- FDA Guidance on Sterile Compounding Audits
- The FDA Safety Reporting Portal and Compounded Products
- FDA Import Refusals at the Border: Compounded GLP-1 Products
- FDA and the Federal-State Compounding Pharmacy Task Force
- FDA Approach to Compounded Peptides in Veterinary Medicine
- FDA Data Integrity Initiatives and Compounding
- Congressional Budget Requests for FDA Compounding Oversight